Results 181 to 190 of about 132,043 (333)

Clinofibrate Disrupts the SNORA80B/YTHDC1‐Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC

open access: yesAdvanced Science, Volume 13, Issue 3, 14 January 2026.
This study uncovers a non‐canonical role of SNORA80B in ESCC, showing it mediates AR‐driven metabolic reprogramming via N⁶‐methyladenosine (m6A) methylation. By binding YTHDC1, SNORA80B stabilizes cholesterol‐metabolic enzyme mRNAs and promotes tumor progression. The FDA‐approved drug clinofibrate inhibits SNORA80B by disrupting cholesterol homeostasis,
Hongyu Yuan   +7 more
wiley   +1 more source

Nationwide Survey of the Surgical Treatment for Hiatal Hernia in Japan

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 1, Page 113-127, January 2026.
This nationwide study of 960 hiatal hernia surgeries in Japan found that patients with Type I hernia had distinct characteristics and more favorable surgical outcomes compared to Types II–IV. Postoperative dysphagia was significantly associated with Types II–IV, preoperative dysphagia, and esophageal strictures, highlighting the need for careful ...
Soji Ozawa   +8 more
wiley   +1 more source

Ambulatory Esophageal pH Monitoring in Gastroesophageal Reflux Disease

open access: yesCanadian Journal of Gastroenterology, 1992
Joel E Richter, Swarnjit Singh
doaj   +1 more source

A Dual‐Locking G‐Quadruplex DNA Targeting Strategy Based on a Tumor‐Accumulating Porphyrin‐Ruthenium(II) Conjugate for Type I Photodynamic Therapy

open access: yesAggregate, Volume 7, Issue 1, January 2026.
This study identifies PorRu as a “dual‐lock” G‐quadruplex binder, which also serves as a tumor‐targeting Type I photosensitizer. This agent overcomes the limitations of oxygen‐dependent PDT, providing a novel strategy for precise HCC therapy. ABSTRACT The hypoxic tumor microenvironment severely limits the effectiveness of photodynamic therapy (PDT) in ...
Qiong Wu   +6 more
wiley   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

open access: yesChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh   +7 more
wiley   +1 more source

Pancreatic Pseudocyst With Thoracic Extension: A Clinicoradiological Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
CECT sagittal view shows an enlarged, heterogeneously enhancing pancreas with a peripancreatic collection extending into the posterior mediastinum and compressing the esophagus with massive right pleural fluid noted. ABSTRACT Pancreatic pseudocysts are encapsulated, enzyme‐rich peripancreatic fluid collections that typically develop following acute or ...
Sachchu Thapa   +7 more
wiley   +1 more source

Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance

open access: yesClinical and Translational Medicine, Volume 16, Issue 1, January 2026.
TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI ...
Ying Ning   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy